2-Methoxy-5-Amino-<i>N</i>-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression

Molecular Cancer Therapeutics - Tập 10 Số 10 - Trang 1969-1981 - 2011
Carmine Stolfi1, Roberta Caruso1, Eleonora Franzè1, Angelamaria Rizzo1, Angela Rotondi1, Ivan Monteleone1, Massimo Claudio Fantini1, Francesco Pallone1, Giovanni Monteleone1
1Authors' Affiliation: Department of Internal Medicine, University of Tor Vergata, Rome, Italy

Tóm tắt

Abstract TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis is a crucial event in the control of tumor growth. However, many cancer cells, including colon cancer cells, are resistant to TRAIL-driven cell death. We have recently shown that 2-methoxy-5-amino-N-hydroxybenzamide (herein termed 2-14), a novel derivative of mesalamine, induces endoplasmic reticulum stress in colon cancer cells. Because endoplasmic reticulum stress-induced signals regulate the expression of molecules involved in TRAIL-driven apoptosis, we examined whether 2-14 makes colon cancer cells sensitive to TRAIL. Colon cancer cells were cultured with 2-14 and/or TRAIL. Death receptor (DR) 4/DR5 were analyzed by real-time PCR and flow cytometry. TRAIL pathway–associated proteins and extracellular signal–regulated kinase (ERK) were assessed by Western blotting. The in vivo capability of 2-14 to sensitize colon cancer cells to TRAIL-induced apoptosis was evaluated in a syngenic colon cancer model in which CT26-derived grafts were induced in mice. 2-14 promoted ERK-dependent induction of DR5, thereby enhancing TRAIL-mediated caspase-8 activation and apoptosis. Analysis of TRAIL-related pro- and antiapoptotic factors and functional studies revealed that survivin is involved in the protection of colon cancer cells against TRAIL-driven apoptosis. Notably, 2-14 enhanced ubiquitination and proteasome-mediated degradation of survivin. These data were confirmed in a murine model of TRAIL-resistant colon cancer in which 2-14 upregulated DR5, reduced survivin expression, and synergized with TRAIL in inhibiting tumor growth. Similarly, intraperitoneal administration of 2-14 to mice upregulated DR5 and downregulated survivin in a model of colitis-associated colon cancer. These findings indicate that 2-14 acts as a sensitizer for TRAIL-induced apoptosis and suggest that 2-14 can be useful in the therapy for TRAIL-resistant colon cancer. Mol Cancer Ther; 10(10); 1969–81. ©2011 AACR.

Từ khóa


Tài liệu tham khảo

Wiley, 1995, Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3, 673, 10.1016/1074-7613(95)90057-8

LeBlanc, 2003, Apo2L/TRAIL and its death and decoy receptors, Cell Death Differ, 10, 66, 10.1038/sj.cdd.4401187

Carlo-Stella, 2007, Targeting TRAIL agonistic receptors for cancer therapy, Clin Cancer Res, 13, 2313, 10.1158/1078-0432.CCR-06-2774

Sheridan, 1997, Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors, Science, 277, 818, 10.1126/science.277.5327.818

Truneh, 2000, Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor, J Biol Chem, 275, 23319, 10.1074/jbc.M910438199

Ashkenazi, 1998, Death receptors: signaling and modulation, Science, 281, 1305, 10.1126/science.281.5381.1305

Kelley, 2004, Targeting death receptors in cancer with Apo2L/TRAIL, Curr Opin Pharmacol, 4, 333, 10.1016/j.coph.2004.02.006

Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest, 104, 155, 10.1172/JCI6926

Walczak, 1999, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat Med, 5, 157, 10.1038/5517

Pukac, 2005, HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo, Br J Cancer, 92, 1430, 10.1038/sj.bjc.6602487

Ichikawa, 2001, Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity, Nat Med, 7, 954, 10.1038/91000

Todaro, 2008, Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4, Cell Death Differ, 15, 762, 10.1038/sj.cdd.4402305

MacFarlane, 2002, Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia, Oncogene, 21, 6809, 10.1038/sj.onc.1205853

Call, 2008, Targeted manipulation of apoptosis in cancer treatment, Lancet Oncol, 9, 1002, 10.1016/S1470-2045(08)70209-2

Camidge, 2008, Apomab: an agonist monoclonal antibody directed against death receptor 5/TRAIL-receptor 2 for use in the treatment of solid tumors, Expert Opin Biol Ther, 8, 1167, 10.1517/14712598.8.8.1167

Trarbach, 2010, Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer, Br J Cancer, 102, 506, 10.1038/sj.bjc.6605507

Drosopoulos, 2005, Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway, J Biol Chem, 280, 22856, 10.1074/jbc.M412483200

Kawasaki, 1998, Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer, Cancer Res, 58, 5071

Van Geelen, 2004, Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy, Drug Resist Updat, 7, 345, 10.1016/j.drup.2004.11.002

Velayos, 2005, Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies, Am J Gastroenterol, 100, 1345, 10.1111/j.1572-0241.2005.41442.x

Rubin, 2006, Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis, Clin Gastroenterol Hepatol, 4, 1346, 10.1016/j.cgh.2006.08.014

Stolfi, 2008, Molecular basis of the potential of mesalazine to prevent colorectal cancer, World J Gastroenterol, 14, 4434, 10.3748/wjg.14.4434

Monteleone, 2006, Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells, Cell Death Differ, 13, 202, 10.1038/sj.cdd.4401733

Frieri, 1999, Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment, Aliment Pharmacol Ther, 13, 1413, 10.1046/j.1365-2036.1999.00642.x

Stolfi, 2010, Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine, Gastroenterology, 138, 221, 10.1053/j.gastro.2009.08.062

Fulda, 2004, Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol, Cancer Res, 64, 337, 10.1158/0008-5472.CAN-03-1656

Chen, 2007, Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response, Carcinogenesis, 28, 2328, 10.1093/carcin/bgm173

Lu, 2008, Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels, Clin Cancer Res, 14, 3168, 10.1158/1078-0432.CCR-07-4362

Wells, 2008, Flow cytometric mean fluorescence intensity: the biophysics behind the number, Leukemia Res, 32, 845, 10.1016/j.leukres.2007.10.002

Lacour, 2001, Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis, Cancer Res, 61, 1645

Shenoy, 2009, LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors, Cancer Res, 69, 1941, 10.1158/0008-5472.CAN-08-1996

Sung, 2010, Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL, J Biol Chem, 285, 35418, 10.1074/jbc.M110.172767

Yamaguchi, 2004, CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells, J Biol Chem, 279, 45495, 10.1074/jbc.M406933200

Gimenez-Bonafe, 2009, Overcoming drug resistance by enhancing apoptosis of tumor cells, Curr Cancer Drug Targets, 9, 320, 10.2174/156800909788166600

Krueger, 2001, FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis, Mol Cell Biol, 21, 8247, 10.1128/MCB.21.24.8247-8254.2001

Tran, 2002, A role for survivin in chemoresistance of endothelial cells mediated by VEGF, Proc Natl Acad Sci U S A, 99, 4349, 10.1073/pnas.072586399

Morgillo, 2006, Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib, Cancer Res, 66, 10100, 10.1158/0008-5472.CAN-06-1684

Zhao, 2000, The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner, J Cell Sci, 113, 4363, 10.1242/jcs.113.23.4363

Zauli, 2006, The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology, Cytokine Growth Factor Rev, 17, 245, 10.1016/j.cytogfr.2006.04.002

Lin, 2008, CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells, Cancer Res, 68, 5335, 10.1158/0008-5472.CAN-07-6209

Yeh, 2009, Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression, Mol Cancer Ther, 8, 2718, 10.1158/1535-7163.MCT-09-0211

Zou, 2007, PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells, Cancer Biol Ther, 6, 99, 10.4161/cbt.6.1.3555

Elrod, 2008, Modulation of death receptors by cancer therapeutic agents, Cancer Biol Ther, 7, 163, 10.4161/cbt.7.2.5335

Schwab, 2008, PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells, Carcinogenesis, 29, 1407, 10.1093/carcin/bgn118

Altieri, 2003, Survivin, versatile modulation of cell division and apoptosis in cancer, Oncogene, 22, 8581, 10.1038/sj.onc.1207113

Ambrosini, 1997, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med, 3, 917, 10.1038/nm0897-917

Thông tin
Thông tin xuất bản

Molecular Cancer Therapeutics

Tập 10 Số 10

1969-1981

Thông tin tác giả